A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3425-3431

  Nieto, Yago ^a   Cagnoni, Pablo J ^a   Shpall, Elizabeth J ^a   Xu, Xuesheng ^a   Murphy, James ^a   Vredenburgh, James ^b   Chao, Nelson J ^b   Bearman, Scott I ^a   Jones, Roy B ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MODEL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; STEM CELL TRANSPLANTATION; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARMUSTINE; CISPLATIN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0032730636     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, systemic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339: 1-15, 1992.
2. Bonadonna, G., and Valagussa, P. Adjuvant systemic therapy for resectable breast cancer. J. Clin. Oncol., 3: 259-275, 1985.
3. Bonadonna, G., Zambetti, M., and Valagussa, P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. J. Am. Med. Assoc., 273: 542-547, 1995.
4. Jaiesimi, I. A., Buzdar, A. U., Hortobagyi G. Inflammatory breast cancer: a review. J. Clin. Oncol., 10: 1014-1024, 1992.
5. Frei, E., III, and Canellos, G. P. Dose. A critical factor in cancer chemotherapy. Am. J. Med., 69: 585-594, 1980.
6. Frei, E., III, Antman, K., Teicher, B., Eder, P., and Schnipper, L. Bone marrow autotransplantation for solid tumors - prospects. J. Clin. Oncol., 4: 515-526, 1989.
7. Bearman, S. I., Overmoyer, B. A., Bolwell, B. J., Taylor, C. W., Shpall, E. J., Cagnoni, P. J., Mechling, B. E., Ronk, B., Baron, A. E., Purdy, M. H., Ross, M., and Jones, R. B. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. Bone Marrow Transplant, 20: 931-937, 1997.
8. De Graaf, H., Willemse, P. H. B., De Vries, E. G. E., Sleijfer, D. T., Mulder, P. O., van der Graaf, W. T., Smit Siblinga, C. T., van der Ploeg, E., Dolsma, W. V., and Mulder, N. H. Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. Eur. J. Cancer, 30A: 150-153, 1994.
9. Peters, W. P., Berry, D., Vredenburgh, J. J., Hussein, A., Rubin, P., Elkordy, M., Ross, M., Henderson, I. C., Budman, D., Norton, L., Weiss, R., and Hurd, D. Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving ≥ 10 axillary lymph nodes (Duke/ CALGB 8782). Proc. Am. Soc. Clin. Oncol., 14: 317a, 1995.
10. Gianni, A. M., Siena, S., Bregni, M., Di Nicola, M., Orefice, S., Cusumano, F., Salvadori, B., Luini, A., Greco, M., Zucali, R., Rilke, F., Zambetti, M., Valagussa, P., and Bonadonna, G. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary lymph nodes: five year results. J. Clin. Oncol., 15: 2312-2321, 1997.
11. Ayash, L. J., Elias, A., Ibrahim, J., Schwartz, G., Wheeler, C., Reich, E., Lynch, C., Warren, D., Shapiro, C., Richardson, P., Hurd, D., Schnipper, L., Frei, E., III, and Antman, K. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J. Clin. Oncol., 16: 1000-1007, 1998.
12. Cagnoni, P. J., Nieto, Y., Shpall, E. J., Bearman, S. I., Baron, A. E., Ross, M., Matthes, S., Dunbar, S. E., and Jones, R. B. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J. Clin. Oncol., 16: 1661-1668, 1998.
13. Peters, W. P., Rosner, G., Vredenburgh, J., Shpall, E., Crump, M., Richardson, P., Marks, L., Cirrincione, C., Wood, W., Henderson, I., Hurd, D., and Norton, L. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc. Am. Soc. Clin. Oncol., 18: 1a, 1999.
14. Bezwoda, W. R. Randomised, controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer. Proc. Am. Soc. Clin. Oncol., 18: 2a, 1999.
15. b supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proc. Am. Soc. Clin. Oncol., 18: 2a, 1999.
16. Somlo, G., Doroshow, J. H., Forman, S. J., Odom-Maryon, T., Lee, J., Chow, W., Hamasaki, V., Leong, L., Morgan, R., Jr., Margolin, K., Raschko, J., Shibata, S., Tetef, M., Yen, Y., Simpson, J., and Molina, A. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J. Clin. Oncol., 15: 2882-2893, 1997.
17. Elston, C. W., and Ellis, I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19: 403-410, 1991.
18. Hedley, D. W., Clark, G. M., Cornelisse, C. J., Killander, D., Kute, T., and Merkel, D. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry, 14: 482-485, 1993.
19. Clark, G. M., Mathieu, M-C., Owens, M. A., Dressler, L. G., Eudey, L., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M. D., and McGuire, W. L. Prognostic significance of S-phase fraction in good-risk node-negative breast cancer patients. J. Clin. Oncol., 10: 428-432, 1992.
20. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
21. Peto, R., and Peto J. Regression models and life tables. J. R. Stat. Soc. A, 135: 185-188, 1972.
22. Cox, D. R. Regression models and life tables. J. R. Stat. Soc. B, 34: 187-220, 1972.
23. American Joint Committee on Cancer. Manual for staging of cancer. In: O. Beahrs, D. Hensen, R. Hutter, et al., (eds.), Manual for Staging of Cancer, p. 149. Philadelphia: J. B. Lippincott, 1992.
24. Clark, G. M. Prognostic and predictive factors. In: J. R. Harris, M. E. Lippman, M. Morrow, and S. Hellman (eds), Diseases of the Breast, pp 461-485. Lippincott-Raven, 1996.
25. Fisher, B., and Slack, N. H. Number of lymph nodes examined and the prognosis of breast carcinoma. Surg. Gynecol. Obstet., 131: 79-88, 1970.
26. Fisher, B., Wolmark, N., Bauer, M., Remond, C., and Gebhardt, M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg. Gynecol. Obstet., 152: 765-772, 1981.
27. Fisher, B., Brown, A., Mamounas, E., Wieand, S., Robidoux, A., Margolese, R. G., Cruz, A. B., Jr., Fisher, E. R., Wickerham, D. L., Wolmark, N., DeCillis, A., Hoehn, J. L., Lees, A. W., and Dimitrov, N. V. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J. Clin. Oncol., 15: 2483-2493, 1997.
28. Kuerer, H. M., Newman, L. A., Buzdar, A. U., Dhingra, K., Hunt, K. K., Buchholz, T. A., Binkley, S. M., Strom, E. A., Ames, F. C., Ross, M. I., Feig, B. W., McNeese, M. D., Hortobagyi, G. N., and Singletary, S. E. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J. Sci. Am., 4: 230-236, 1998.
29. McCready, D. R., Hortobagyi, G. N., Kau, S. W., Smith, T. L., Buzdar, A. U., and Balch, C. M. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch. Surg., 124: 21-25, 1989.
30. Botti, C., Vici, P., Lopez, M., Scinto, A. F., Cognetti, F., and Cavaliere, R. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J. Am. Coll. Surg., 181: 202-208, 1995.
31. Brain, E., Garrino, C., Misset, J-L., Carbonero, I. G., Itzhaki, M., Cvitkovic, E., Goldschmidt, E., Burki, F., Regensberg, C., Pappo, E., Hagipantelli, R., and Musset, M. Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. Br. J. Cancer, 75: 1360-1367, 1997.
32. Machiavelli, M. R., Romero, A. O., Perez, J. E., Lacava, J. A., Dominguez, M. E., Rodriguez, R., Barbieri, M. R., Romero Acuña, J. M., Langhi, M. J., Amato, S., Ortiz, E. H., Vallejo, C. T., and Leone, B. A. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J. Sci. Am., 4: 125-131, 1998.
33. Frierson, H. F., Jr., and Fechner, R. E. Histologic grade of locally advanced infiltrating ductal carcinoma after treatment with induction chemotherapy. Am. J. Clin. Pathol., 102: 154-157, 1994.
34. Sharkey, F. E., Addington, S. L., Fowler, L. J., Page, C. P., and Cruz, A. B. Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. Mod. Pathol., 9: 893-900, 1996.
35. Honkoop, A. H., Pinedo, H. M., De Jong, J. S., Verheul, H. M., Linn, S. C., Hoekman, K., Wagstaff, J., and van Diest, P. J. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am. J. Clin. Pathol., 107: 211-218, 1997.
36. Schoenfeld, A., Kruger, K. H., Gomm, J., Sinnett, H. D., Gazet, J. C., Sacks, N., Bender, H. G., Luqmani, Y., and Coombes, R. C. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur. J. Cancer, 33: 854-861, 1997.
37. Datta, Y. H., Adams, P. T., Drobyski, W. R., Ethier, S. P., Terry, V. H., and Roth, M. S. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase cham reaction. J. Clin. Oncol., 12: 475-482, 1994.
38. Fields, K., Moscinski, L., Trudeau, W., and Elfenbein, G. The use of polymerase chain reaction (PCR) for amplification of cytokeratin 19 to detect bone marrow micrometastases in breast cancer. Proc. Am. Soc. Clin. Oncol., 13: 115a, 1994.
39. Franklin, W. A., Shpall, E. J., Archer, P., Johnston, C. S., Garza-Williams, S., Hami, L., Bitter, M. A., Bast, R. C., and Jones, R. B. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res. Treat., 41: 1-13, 1996.
40. Vredenburgh, J. J., Silva, O., Broadwater, G., Berry, D., DeSombre, K., Tyer, C., Petros, W. P., Peters, W. P., and Bast, R. C., Jr. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol. Blood Marrow Transplant., 3: 91-97, 1997.
41. Umiel, T., Moss, T. J., Cooper, B., Kennedy, M. J., Meagher, R., Pecora, A. L., Herzig, R. M., Copelan, E., Lazarus, H. M., and Rosenfeld, C. S. The prognostic value of bone marrow micrometastases in stage II/III breast cancer patients undergoing autologous transplant (ABMT) therapy. Proc. Am. Soc. Clin. Oncol., 17: 79a, 1998.